Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $36 to $49.
Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $36 to $49.